The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study
Open accessAbstract
OBJECTIVE: To determine the efficacy and safety of deutetrabenazine as a treatment for tardive dyskinesia (TD). METHODS: One hundred seventeen patients with moderate to severe TD received deutetrabenazine or placebo in this randomized, double-blind, multicenter trial. Eligibility criteria included an Abnormal Involuntary Movement Scale (AIMS) score of ≥6 assessed by blinded central video rating, stable psychiatric illness, and stable psychoactive medication treatment. Primary endpoint was the change in AIMS score from baseline to week 12. Secondary endpoints included treatment success at week 12 on the Clinical Global Impression of Change (CGIC) and Patient Global Impression of Change. RESULTS: = 0.019). Treatment success on CGIC (48.2% vs 40.4%) favored deutetrabenazine but was not significant. Deutetrabenazine and placebo groups showed low rates of psychiatric adverse events: anxiety (3.4% vs 6.8%), depressed mood/depression (1.7% vs 1.7%), and suicidal ideation (0% vs 1.7%, respectively). In addition, no worsening in parkinsonism, as measured by the Unified Parkinson's Disease Rating Scale motor subscale, was noted from baseline to week 12 in either group. CONCLUSIONS: In patients with TD, deutetrabenazine was well tolerated and significantly reduced abnormal movements. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that in patients with TD, deutetrabenazine reduces AIMS scores.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial
Huntington Study Group (2006) · Neurology · doi:10.1212/01.wnl.0000198586.85250.13 · Cited by 471
Huntington Study Group, Frank, S., Testa, C. M., Stamler, D., Kayson, E., Davis, C., Edmondson, M. C., Kinel, S., Leavitt, B., Oakes, D., et al. (2016) · JAMA · doi:10.1001/jama.2016.8655 · Cited by 403
Self-citationTetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial
Savani, A. A., & Login, I. S. (2007) · Neurology · doi:10.1212/01.wnl.0000259143.52138.5c · Cited by 299
Bhidayasiri, R., Fahn, S., Weiner, W. J., Gronseth, G. S., Sullivan, K. L., & Zesiewicz, T. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31829d86b6 · Cited by 211
An Update on Tardive Dyskinesia: From Phenomenology to Treatment
Waln, O., & Jankovic, J. J. (2013) · PubMed · doi:10.7916/d88p5z71 · Cited by 198
Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.
Caroff, S. N., Hurford, I., Lybrand, J., & Campbell, E. C. (2011) · Neurologic Clinics · doi:10.1016/j.ncl.2010.10.002 · Cited by 188 · cited 1×
“These results are of particular importance because antipsychotic discontinuation or dose reduction is often not possible for patients with TD because of the high risk of psychotic exacerbation.(9) Moreover, deutetrabenazine did not result in reports of depression or suicidal ideation and was associated with low rates…”
BackgroundWoods, S. W., Morgenstern, H., Saksa, J. R., Walsh, B. C., Sullivan, M. C., Money, R., Hawkins, K. A., Gueorguieva, R. V., & Glazer, W. M. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07m03890yel · Cited by 186
Self-citationMethods to improve reliability of video‐recorded behavioral data
Haidet, K. K., Tate, J., Divirgilio‐Thomas, D., Kolanowski, A., & Happ, M. B. (2009) · Research in Nursing & Health · doi:10.1002/nur.20334 · Cited by 184
Longitudinal Psychiatric Symptoms in Prodromal Huntington’s Disease: A Decade of Data
Epping, E. A., Kim, J., Craufurd, D., Brashers-Krug, T. M., Anderson, K. E., McCusker, E. A., Luther, J., Long, J. D., Paulsen, J. S., & PREDICT-HD Investigators and Coordinators of the Huntington Study Group (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14121551 · Cited by 178
Self-citationTetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders
Guay, D. R. P. (2010) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2010.08.006 · Cited by 146
Cited by
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Management of common adverse effects of antipsychotic medications
Stroup, T. S., & Gray, N. (2018) · World Psychiatry · doi:10.1002/wps.20567 · Cited by 572
Anderson, K. E., Stamler, D., Davis, M. D., Factor, S. A., Hauser, R. A., Isojärvi, J., Jarskog, L. F., Jimenez-Shahed, J., Kumar, R., McEvoy, J. P., et al. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30236-5 · Cited by 337
Self-citationWhat is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia?
Correll, C. U., Rubio, J. M., & Kane, J. M. (2018) · World Psychiatry · doi:10.1002/wps.20516 · Cited by 324
Solmi, M., Pigato, G., Kane, J. M., & Correll, C. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s133205 · Cited by 88
Metadata
- Authors
- Fernandez, H. H., Factor, S. A., Hauser, R. A., Jimenez-Shahed, J., Ondo, W. G., Jarskog, L. F., Meltzer, H. Y., Woods, S. W., Bega, D., LeDoux, M. S., Shprecher, D. R., Davis, C., Davis, M. D., Stamler, D., & Anderson, K. E.
- Venue
- Neurology
- Published
- 2017-05-23
- Volume
- 88
- Issue
- 21
- Pages
- 2003-2010
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2609324068
- Cited by
- 327
- References
- 20
- FWCI
- 49.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. https://app.cochat.ai/papers/10.1212/wnl.0000000000003960
- The paper
- Fernandez, H. H., Factor, S. A., Hauser, R. A., Jimenez-Shahed, J., Ondo, W. G., Jarskog, L. F., Meltzer, H. Y., Woods, S. W., Bega, D., LeDoux, M. S., Shprecher, D. R., Davis, C., Davis, M. D., Stamler, D., & Anderson, K. E. (2017). Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study. Neurology. https://doi.org/10.1212/wnl.0000000000003960
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.